EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Polymer-Drug Conjugates as Nanotheranostic Agents

Sajana Manandhar, Erica Sjöholm, Johan Bobacka, Jessica M. Rosenholm, Kuldeep K. Bansal

Journal of Nanotheranostics · 13.03.2021 · 2 (1) · 63-81

DOI: 10.3390/jnt2010005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nanotheranostics, online erschienen am 13.03.2021. Verfasst von Sajana Manandhar und 4 weiteren Autor:innen. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Finland, Erasmus+ Programme of the European Union, Sigrid Juséliuksen Säätiö.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the last decade, the polymer-drug conjugate (PDC) approach has emerged as one of the most promising drug-delivery technologies owing to several benefits like circumventing premature drug release, offering controlled and targeted drug delivery, improving the stability, safety, and kinetics of conjugated drugs, and so forth. In recent years, PDC technology has advanced with the objective to further enhance the treatment outcomes by integrating nanotechnology and multifunctional characteristics into these systems. One such development is the ability of PDCs to act as theranostic agents, permitting simultaneous diagnosis and treatment options. Theranostic nanocarriers offer the opportunity to track the distribution of PDCs within the body and help to localize the diseased site. This characteristic is of particular interest, especially among those therapeutic approaches where external stimuli are supposed to be applied for abrupt drug release at the target site for localized delivery to avoid systemic side effects (e.g., Visudyne®). Thus, with the help of this review article, we are presenting the most recent updates in the domain of PDCs as nanotheranostic agents. Different methodologies utilized to design PDCs along with imaging characteristics and their applicability in a wide range of diseases, have been summarized in this article.

Förderung

  • Academy of Finland
  • Erasmus+ Programme of the European Union
  • Sigrid Juséliuksen Säätiö

Zitieren

APA

Manandhar, S., Sjöholm, E., Bobacka, J., Rosenholm, J. M., & Bansal, K. K. (2021). Polymer-Drug Conjugates as Nanotheranostic Agents. Journal of Nanotheranostics, 2(1), 63-81. https://doi.org/10.3390/jnt2010005

Vancouver

Manandhar S, Sjöholm E, Bobacka J, Rosenholm JM, Bansal KK. Polymer-Drug Conjugates as Nanotheranostic Agents. Journal of Nanotheranostics. 2021;2(1):63-81. doi:10.3390/jnt2010005

BibTeX
@article{Manandhar2021,
  author = {Manandhar, Sajana and Sjöholm, Erica and Bobacka, Johan and Rosenholm, Jessica M. and Bansal, Kuldeep K.},
  title = {Polymer-Drug Conjugates as Nanotheranostic Agents},
  journal = {Journal of Nanotheranostics},
  year = {2021},
  volume = {2},
  number = {1},
  pages = {63--81},
  doi = {10.3390/jnt2010005}
}
Kostenlos starten →